CD4+T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides

Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder resulting from the development of autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). HLA-DRB1*11 provides a risk factor for developing acquired TTP. Pulsing of antigen-presenting cells from HLA-DRB1*11– and HLA-DRB1*03–positive individuals with ADAMTS13 resulted in presentation of peptides derived from the CUB2 domain of ADAMTS13 with core sequences FINVAPHAR or ASYILIRD. Here, we assessed whether FINVAPHAR- or ASYILIRD-reactive CD4+T cells are present in peripheral blood mononuclear cells from HLA-DRB1*11 and HLA-DRB1*03–positive subjects with acquired TTP. The presence of ADAMTS13-reactive CD4+T cells was addressed by flow cytometry and the expression of activation marker CD40 ligand by CD4+T cells. FINVAPHAR-reactive CD4+T cells were identified in an HLA-DRB1*11–positive patient during the acute phase of the disease whereas ASYILIRD-positive CD4+T cells were identified in a DRB1*03-positive patient with acquired TTP. Frequencies of CUB2 domain-reactive CD4+T cells ranged from 3.3% to 4.5%. Control peptides in which the anchor residues were modified did not induce activation of CD4+T cells. Taken together, our data provide evidence for the involvement of CUB2 domain-reactive CD4+T cells in the etiology of acquired TTP.